WeHealth by Servier has partnered with bioelectronic medicine firm PathMaker Neurosystems for the development and commercialisation of a neuromodulation device to non-invasively treat spasticity.
The agreement covers the exclusive distribution of PathMaker’s MyoRegulator device globally, except in the US and Japan.
Based on PathMaker’s DoubleStim technology, MyoRegulator has been designed to deliver simultaneous non-invasive stimulation at spinal and peripheral sites in order to suppress hyperexcitable spinal circuits associated with spasticity.
As part of the collaboration, WeHealth will provide funding support to an ongoing clinical trial being conducted in Europe to assess the neuromodulation device for non-invasive treatment of spasticity secondary to stroke.
WeHealth also agreed to fund another larger European trial meant to support reimbursement coverage.
WeHealth by Servier general director David Guez said: “The MyoRegulator device has clear and groundbreaking benefits for patients with serious neurological conditions.
“Our partnership with PathMaker represents an opportunity for WeHealth to contribute to the advancement of a truly novel technology that is moving the field of bioelectronic medicine forward.”
PathMaker will obtain an upfront payment and clinical/regulatory milestones.
The company will also receive royalties from future sales of the device and disposables (single-use electrodes) in the Servier territories.
PathMaker Neurosystems president and CEO Nader Yaghoubi said: “This significant partnership will provide a large number of patients with access to this breakthrough non-invasive treatment through WeHealth’s international presence in more than 100 countries worldwide.
“We look forward to the positive impact this partnership will have on the patients waiting for meaningful and safe treatment, and on the development of our company.”
In February last year, the company secured $5m, four-year grant from the National Institutes of Health (NIH) to develop the MyoRegulator device.